Molecular Cancer Research · 2011 · 49 citations · 31 references
MedicineMolecular BiologyOncologyChemotherapyGene ExpressionMolecular OncologyCancer Cell SignalingMalignant NeoplasmsOncogenic Signaling PathwaysRna InterferenceSignal Transduction In CancerSmall Interfering Rna BiologyCancer Cell Proliferation InhibitionMedulloblastoma ChemotherapyPhosphoinositide 3-Kinase PathwayPhosphoinositide 3-Kinase SignalingPhosphoinositide 3-Kinase-akt SignalingPi3k SignalingPolo-like Kinase FunctionPolo-like Kinase Inhibition
Medulloblastoma is the most common malignant brain tumor in children and is associated with a poor outcome. We were interested in gaining further insight into the potential of targeting the human kinome as a novel approach to sensitize medulloblastoma to chemotherapeutic agents. A library of small interfering RNA (siRNA) was used to downregulate the known human protein and lipid kinases in medulloblastoma cell lines. The analysis of cell proliferation, in the presence or absence of a low dose of cisplatin after siRNA transfection, identified new protein and lipid kinases involved in medulloblastoma chemoresistance. PLK1 (polo-like kinase 1) was identified as a kinase involved in proliferation in medulloblastoma cell lines. Moreover, a set of 6 genes comprising ATR, LYK5, MPP2, PIK3CG, PIK4CA, and WNK4 were identified as contributing to both cell proliferation and resistance to cisplatin treatment in medulloblastoma cells. An analysis of the expression of the 6 target genes in primary medulloblastoma tumor samples and cell lines revealed overexpression of LYK5 and PIK3CG. The results of the siRNA screen were validated by target inhibition with specific pharmacological inhibitors. A pharmacological inhibitor of p110γ (encoded by PIK3CG) impaired cell proliferation in medulloblastoma cell lines and sensitized the cells to cisplatin treatment. Together, our data show that the p110γ phosphoinositide 3-kinase isoform is a novel target for combinatorial therapies in medulloblastoma.
31
BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo
Martin Steegmaier, Matthias Hoffmann, Anke Baum et al. · Current Biology · 2007 · 849 citations · Full text
Medicine, Oncology, Pharmacology +14
Synthetic lethal screen identification of chemosensitizer loci in cancer cells
Angelique W. Whitehurst, Brian O. Bodemann, Jessica Cardenas et al. · Nature · 2007 · 477 citations
Medicine, Cancer Biology, Oncology +15